T-DXd showed promising activity in the cohort of HER2-positive breast cancer patients (n = 115) pretreated with TDM-1 in the phase 1 trial (NCT02564900; data cut-off August 2018) [23]. Here, ERBB2 is linked to breast carcinoma.